Jpmorgan Chase & CO Bio Affinity Technologies, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BIAF
# of Institutions
16Shares Held
376KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA172KShares$228,7520.0% of portfolio
-
Geode Capital Management, LLC Boston, MA69.6KShares$92,5680.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC27.9KShares$37,0870.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny23KShares$30,5460.0% of portfolio
-
State Street Corp Boston, MA17.6KShares$23,4080.0% of portfolio
About bioAffinity Technologies, Inc.
- Ticker BIAF
- Exchange
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 2,727,580
- Market Cap $3.63M
- Description
- bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...